Penn Medicine Researchers Pinpoint Potential New Drug Target for Protection against Certain Neurodegenerative Diseases
Findings Could Pave Way for Precision Medicine Approach to Treatment of Neurological Diseases.
Penn Medicine researchers have discovered that hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases. Their work, published this month in Neurology, may suggest a neuroprotective target for drug discovery efforts.
IOA in the News
Penn's 4th Annual 5K FOR THE IOA & The Memory Mile Walk
Sunday, September 20th, 2015 | 8:00am @ Penn Park
Shoemaker Green Entrance | On 33rd between Walnut and South Streets
New this year: Dogs on leashes are welcomed for the Memory Mile Walk only!
Join the nearly 300 Institute on Aging Fellows and Associate Fellows and experience robust collaborative opportunities in aging at Penn, for funding opportunity alerts, pilot research grant opportunities, and updates on IOA activities.Get Involved
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team